Loading…
Patient with Stage IV Triple-Negative Breast Cancer shows positive results.
Kazia Therapeutics Limited announced that a patient with Stage IV Triple-Negative Breast Cancer (TNBC) achieved an initial immune-complete response (iCR) in a clinical trial. The trial involved the combination of Paxalisib with Pembrolizumab and standard chemotherapy.
The response was observed in a patient participating in the trial, which is evaluating the efficacy of the combination therapy. No specific amounts or filings were reported in the announcement.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.